Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying all 2 drugs

Ravulizumab

Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking...
Approved
Investigational
Matched Synonyms: … Ravulizumab ... ravulizumab-cwvz …
Matched Name: … Ravulizumab …
Matched Description: … Ravulizumab is a potent and selective complement 5 (C5) inhibitor. ... nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults. ... [L39710] Ravulizumab is also used to treat myasthenia gravis. …
Matched Categories: … ravulizumab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Danicopan

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. eculizumab, ravulizumab) which are effective in mitigating complement-mediated intravascular...
Approved
Investigational
Matched Description: … [eculizumab], [ravulizumab]) which are effective in mitigating complement-mediated intravascular hemolysis ... and thromboembolism. ... [A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying all 2 drugs